{"id":"W4284989117","doi":"10.1016/j.jaad.2022.07.002","title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","year":2022,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":347,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research; Queen's University","funders":"Manchester Biomedical Research Centre; Bristol-Myers Squibb Canada; Bristol-Myers Squibb","keywords":"Medicine; Apremilast; Placebo; Psoriasis; Double blinded; Randomized controlled trial; Plaque psoriasis; Internal medicine; Dermatology; Alternative medicine; Psoriatic arthritis; Pathology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001514245,0.0003709573,0.002216283,0.0002714759,0.0004244768,0.00002169925,0.0007061337,0.0002161778,0.00004454451],"category_scores_gemma":[0.0007514546,0.0002266471,0.000371694,0.0003583996,0.0007495539,0.0001037726,0.0003688646,0.001139096,0.000005195683],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008590978,"about_ca_system_score_gemma":0.0001846693,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001887656,"about_ca_topic_score_gemma":0.00003242555,"domain_scores_codex":[0.9933926,0.003940207,0.001653962,0.0003908324,0.0001697059,0.0004527107],"domain_scores_gemma":[0.9899014,0.007605561,0.002108345,0.0002534309,0.00004808718,0.00008313402],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9874827,0.0003785228,0.00009244896,0.000004417894,0.001881345,0.00002797393,0.001587137,0.000366181,0.002198582,0.0001701507,0.001627272,0.004183309],"study_design_scores_gemma":[0.9872305,0.0008413755,0.0002890777,0.0000437277,0.0009847229,0.001368652,0.001375999,0.00004738946,0.00265605,0.0001652624,0.004765731,0.0002315241],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9741471,0.003124166,0.00002323414,0.01919961,0.00085834,0.002123087,0.0003241702,0.00001308586,0.0001872066],"genre_scores_gemma":[0.9977323,0.000981346,0.0001447295,0.0007606777,0.0001192098,0.000127914,0.00001787614,0.00002440428,0.00009158666],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02358516,"threshold_uncertainty_score":0.9242399,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03301569140574727,"score_gpt":0.3004635964409313,"score_spread":0.2674479050351841,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}